ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis. In addition, it develops CCX559, an orally administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally administered inhibitor of the chemokine receptor known as CCR9, which has completed Phase I clinical trial for the treatment of inflammatory bowel disease. Further, the company has early-stage drug candidates that targets Th17 driven diseases and CCR6. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California. As of October 20, 2022, ChemoCentryx, Inc. operates as a subsidiary of Amgen Inc.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2022-11-08 |
2022-09 |
-0.42 |
N/A |
N/A |
N/A |
2022-08-08 |
2022-06 |
-0.51 |
N/A |
N/A |
N/A |
2022-05-05 |
2022-03 |
-0.3 |
N/A |
N/A |
N/A |
2022-03-01 |
2021-12 |
-0.57 |
N/A |
N/A |
N/A |
2021-11-09 |
2021-09 |
-0.46 |
N/A |
N/A |
N/A |
2021-08-09 |
2021-06 |
-0.55 |
N/A |
N/A |
N/A |
Date |
Firm |
Action |
From |
To |
2022-08-10 |
Stifel |
Downgrade |
Buy |
Hold |
2022-08-05 |
SVB Leerink |
Downgrade |
Outperform |
Market Perform |
2022-08-05 |
HC Wainwright & Co. |
Downgrade |
Buy |
Neutral |
2022-08-05 |
Canaccord Genuity |
Downgrade |
Buy |
Hold |
2022-08-05 |
Raymond James |
Downgrade |
Strong Buy |
Market Perform |
2022-05-06 |
Raymond James |
Upgrade |
|
Strong Buy |
Date |
Name |
Relation |
Quantity |
Description |
2022-08-03 |
CAPPEL MARKUS J |
Officer and Treasurer |
87.66K |
Sale |
2022-05-25 |
EDWARDS THOMAS A |
Director |
143.31K |
Stock Award(Grant) |
2022-01-20 |
FECZKO JOSEPH M |
Director |
148.13K |
Conversion of Exercise of derivative security |
2022-06-27 |
HERRON JENNIFER LYN |
Director |
17.24K |
Stock Award(Grant) |
2022-05-19 |
JAIN RITA |
Officer and Director |
35.86K |
Conversion of Exercise of derivative security |
2022-08-15 |
KANAYA SUSAN M |
Chief Financial Officer |
224.03K |
Sale |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2022-06-29 |
FMR, LLC |
10.68M |
555.20M |
14.97% |
2022-06-29 |
Vanguard Group, Inc. (The) |
5.81M |
301.87M |
8.14% |
2022-06-29 |
Blackrock Inc. |
4.64M |
241.11M |
6.50% |
2022-06-29 |
State Street Corporation |
4.05M |
210.35M |
5.67% |
2022-06-29 |
Pictet Asset Management SA |
2.37M |
123.35M |
3.33% |
2022-06-29 |
Wasatch Advisors Inc |
2.10M |
109.33M |
2.95% |
Report Date |
Organization |
Position |
Value |
Percentage |
2022-06-29 |
Vanguard Total Stock Market Index Fund |
1.88M |
97.97M |
2.64% |
2022-06-29 |
Vanguard Small-Cap Index Fund |
1.62M |
84.07M |
2.27% |
2022-09-29 |
SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF |
1.46M |
76.14M |
2.05% |
2022-09-29 |
iShares Russell 2000 ETF |
1.37M |
71.49M |
1.93% |
2022-06-29 |
Vanguard Small-Cap Growth Index Fund |
954.02K |
49.60M |
1.34% |
2022-06-29 |
Mutual Fund Ser Tr-Eventide Healthcare & Life Sciences Fund |
728.39K |
37.87M |
1.02% |